Alex Lovejoy

Alex Lovejoy has a strong background in molecular research and has worked in various roles throughout their career. They currently hold the position of Director, Molecular Research at Freenome since December 2021. Prior to this, they were an Associate Director, Molecular Research at the same company from June 2021 to December 2021.

Before joining Freenome, Alex worked at Roche Sequencing where they held several positions, including Sr. Manager, Principal Scientist II, Principal Scientist I, and Sr. Scientist. In these roles, they focused on assay development for oncology diagnostics and the detection of circulating tumor DNA (ctDNA) in plasma. They also contributed to research studies on the utility of ctDNA NGS assays in samples from oncology clinical trials and academic collaborations.

Alex's work experience also includes a role as a Postdoctoral Fellow at Stanford Cancer Institute where they focused on optimizing a high throughput sequencing-based assay for the detection of ctDNA in plasma. They also had a previous postdoctoral research position at Stanford Cancer Institute where they worked on identifying the role of pseudouridylation in Toxoplasma development.

Their career started as a Graduate Student at Stanford University Biochemistry Department, where they developed a high-throughput sequencing technique to identify and characterize modifications of mRNA in yeast. They also worked as a Technician at EMD Millipore and as an Undergraduate Researcher at Yale University, where they contributed to a publication related to RNA 3'-end processing.

Overall, Alex Lovejoy has a diverse and extensive work experience in molecular research, with a focus on assay development and the detection of ctDNA in plasma.

Alex Lovejoy received a BS degree in Molecular Biophysics and Biochemistry from Yale University in 2007. Later, from 2008 to 2013, Alex pursued a Ph.D. in Biochemistry at Stanford University School of Medicine.